Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Eur Arch Otorhinolaryngol ; 277(1): 77-83, 2020 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-31605188

RESUMO

PURPOSE: Specially processed cereals (SPC) that increase endogenous antisecretory factor (AF) synthesis have been proposed to improve symptoms of Meniere's disease (MD) with controversial results. The aim of this study was to evaluate the effects of SPC in patients with definite unilateral MD and compare the results to a treatment protocol with intravenous glycerol and dexamethasone. METHODS: Thirteen patients with unilateral MD were treated with SPC and 13 patients were treated with intravenous glycerol and dexamethasone for 12 months. Audio-vestibular evaluation was performed before (T0) and at the end of the treatments (T12). The number of vertigo spells were evaluated before and after therapy and the Efficacy Index (EI) was calculated. Questionnaires for hearing loss (HHIA), tinnitus (THI) and quality of life (TFL) were administered. RESULTS: EI decreased in the SPC group in the second semester compared to the first although not significantly (p = 0.6323). There was a significant reduction for THI score in the SPC group at T12 (p = 0.0325). No significant differences were found between the two groups at T0 (p = 0.4723), while a significant difference was found at T12 (p = 0.0041). Quality of life showed an improvement in daily activities in the SPC group compared to infusion therapy group. CONCLUSION: Our study shows a reduced number of vertigo attacks and a positive effect on the discomfort generated by tinnitus and quality of life in patients with unilateral MD treated with SPC and when compared to patients treated with intravenous glycerol and dexamethasone. No effects on hearing thresholds were noted in both groups.


Assuntos
Grão Comestível/metabolismo , Doença de Meniere/metabolismo , Neuropeptídeos/metabolismo , Fármacos do Sistema Nervoso Periférico/metabolismo , Vertigem/metabolismo , Adulto , Idoso , Dexametasona/administração & dosagem , Feminino , Glicerol/administração & dosagem , Humanos , Masculino , Doença de Meniere/diagnóstico , Doença de Meniere/tratamento farmacológico , Pessoa de Meia-Idade , Fármacos do Sistema Nervoso Periférico/administração & dosagem , Qualidade de Vida , Inquéritos e Questionários , Zumbido/diagnóstico , Zumbido/tratamento farmacológico , Vertigem/tratamento farmacológico , Vertigem/etiologia
2.
J Neurosci Methods ; 330: 108458, 2020 01 15.
Artigo em Inglês | MEDLINE | ID: mdl-31614162

RESUMO

Smoking tobacco products is the leading cause of preventable death worldwide. Coordinated efforts have successfully reduced tobacco cigarette smoking in the United States; however, electronic cigarettes (e-cigarette) and other electronic nicotine delivery systems (ENDS) recently have replaced traditional cigarettes for many users. While the clinical risks associated with long-term ENDS use remain unclear, advancements in preclinical rodent models will enhance our understanding of their overall health effects. This review examines the peripheral and central effects of ENDS-mediated exposure to nicotine and other drugs of abuse in rodents and evaluates current techniques for implementing ENDS in preclinical research.


Assuntos
Estimulantes do Sistema Nervoso Central/efeitos adversos , Sistemas Eletrônicos de Liberação de Nicotina , Nicotina/efeitos adversos , Fármacos do Sistema Nervoso Periférico/efeitos adversos , Vaping/efeitos adversos , Animais , Estimulantes do Sistema Nervoso Central/administração & dosagem , Modelos Animais de Doenças , Nicotina/administração & dosagem , Fármacos do Sistema Nervoso Periférico/administração & dosagem , Ratos , Roedores
3.
Neurosci Lett ; 479(1): 13-7, 2010 Jul 19.
Artigo em Inglês | MEDLINE | ID: mdl-20471453

RESUMO

Bioenergetic deficits are considered a common cause of neurodegenerative diseases. Although creatine supplementation has been shown to be effective in certain neurodegenerative disorders, it is less effective in amyotrophic lateral sclerosis, a disease that primarily affects motor neurons. These neurons are particularly vulnerable to a cellular energy deficit. Using the ATP-depleting drug glucosamine, we evaluated whether the incretin hormone glucagon-like peptide (GLP)-1 protects motor neurons against glucosamine-induced cytotoxicity. Undifferentiated NSC-34 cells were differentiated into glutamate-sensitive motor neurons by a modified serum deprivation technique. Glucosamine inhibited the viability of differentiated NSC-34 cells in a time- and dose-dependent manner. Glucosamine also acutely reduced cellular glucose uptake, glucokinase activity and intracellular ATP levels. As a result, the activity of AMP-activated protein kinase as well as endoplasmic reticulum stress increased. Pretreatment with GLP-1 significantly alleviated glucosamine-mediated neurotoxicity by restoring cellular glucose uptake, glucokinase activity and intracellular ATP levels. The protective effect of GLP-1 was replicated by Exendin-4 but not Exendin-9, and not blocked by inhibitors of phosphoinositide-3 kinase, protein kinase A, cSrc, or epidermal growth factor receptor, but it was blocked by an adenylate cyclase inhibitor. A selective activator for exchange proteins directly activated by cAMP (Epac), but not a selective activator for protein kinase A, mimicked the GLP-1 effect. Therefore GLP-1 may exert its effect mainly through cAMP-dependent, Epac-mediated restoration of glucose uptake that is typically impaired by glucosamine. These findings indicate that GLP-1 could be employed therapeutically to protect motor neurons that are susceptible to bioenergetic deficits.


Assuntos
Peptídeo 1 Semelhante ao Glucagon/metabolismo , Glucosamina/toxicidade , Glucose/metabolismo , Fatores de Troca do Nucleotídeo Guanina/metabolismo , Neurônios Motores/efeitos dos fármacos , Fármacos do Sistema Nervoso Periférico/toxicidade , Proteínas Quinases Ativadas por AMP/metabolismo , Trifosfato de Adenosina/metabolismo , Animais , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Relação Dose-Resposta a Droga , Retículo Endoplasmático/efeitos dos fármacos , Retículo Endoplasmático/enzimologia , Retículo Endoplasmático/metabolismo , Glucoquinase/metabolismo , Glucosamina/administração & dosagem , Células Híbridas , Camundongos , Neurônios Motores/enzimologia , Neurônios Motores/metabolismo , Fármacos do Sistema Nervoso Periférico/administração & dosagem , Estresse Fisiológico/efeitos dos fármacos , Estresse Fisiológico/fisiologia , Fatores de Tempo
4.
Rev Invest Clin ; 62(4): 375-83, 2010.
Artigo em Espanhol | MEDLINE | ID: mdl-21222317

RESUMO

Diabetic neuropathy is the third most common complication of diabetes mellitus. When this neuropathy is accompanied by pain, it requires a specific treatment. In the elderly patient, the pain has an enormous impact on quality of life, as it is associated with anxiety, depression and sleep disorders, leading to a direct impact on the functionality of the patient. Likewise, there are a number of changes at the central and peripheral nervous system, which contribute to the chronicity of painful processes, and eventually also affect and impact on the quality of life of elderly patients. It is fundamental before initiating treatment, to know of all aspects related to drug pharmacokinetics and pharmacodynamics, especially those related to aging, because this will allow you to select the best drug for each patient. This article aims to review the pathophysiological concepts related to diabetic neuropathy in the elderly and the best treatment options.


Assuntos
Analgésicos/uso terapêutico , Nefropatias Diabéticas/tratamento farmacológico , Fármacos do Sistema Nervoso Periférico/uso terapêutico , Psicotrópicos/uso terapêutico , Idoso , Envelhecimento/fisiologia , Analgésicos/administração & dosagem , Analgésicos/efeitos adversos , Analgésicos/farmacocinética , Nefropatias Diabéticas/epidemiologia , Nefropatias Diabéticas/psicologia , Interações Medicamentosas , Humanos , Hipoglicemiantes/administração & dosagem , Hipoglicemiantes/uso terapêutico , Neuralgia/tratamento farmacológico , Neuralgia/etiologia , Neuralgia/psicologia , Neurotransmissores/administração & dosagem , Neurotransmissores/efeitos adversos , Neurotransmissores/farmacocinética , Neurotransmissores/uso terapêutico , Fármacos do Sistema Nervoso Periférico/administração & dosagem , Fármacos do Sistema Nervoso Periférico/efeitos adversos , Fármacos do Sistema Nervoso Periférico/farmacocinética , Polimedicação , Psicotrópicos/administração & dosagem , Psicotrópicos/efeitos adversos , Psicotrópicos/farmacocinética , Qualidade de Vida
5.
Eur Heart J ; 30(18): 2249-53, 2009 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-19556259

RESUMO

AIMS: To compare the responses between clomipramine, a centrally acting substance, and nitroglycerin, with mainly peripheral action, when each drug is used during tilt test for the induction of vasovagal syncope (VVS). METHODS AND RESULTS: Hundred patients with recurrent episodes of classical VVS underwent two tilt tests in a randomized sequence. One test included 20 min of tilt at 60 degrees with intravenous administration of 5 mg clomipramine (clomipramine tilt), whereas the other test included an initial 30 min period of passive 60 degrees tilt, followed by sublingual spray administration of 400 microg nitroglycerin (nitroglycerin tilt). Fifty asymptomatic subjects served as controls. Following clomipramine tilt, a positive response occurred in 73 patients (73%), a negative response in 23 (23%), and drug intolerance in 4 (4%). With nitroglycerin tilt, these percentages were 52, 48, and 0%, respectively. Significant differences were observed regarding positive responses (clomipramine vs. nitroglycerin: 73/100 vs. 52/100, P < 0.05), as well as negative responses (23/100 vs. 48/100, respectively, P < 0.05). A high concordance rate was observed in positive responses. CONCLUSION: In the evaluation of patients with recurrent classical VVS, clomipramine tilt is associated with an increased positive yield relative to nitroglycerin tilt. This suggests that central mechanisms may be more important than peripheral ones in VVS pathogenesis.


Assuntos
Fármacos do Sistema Nervoso Central , Clomipramina , Nitroglicerina , Fármacos do Sistema Nervoso Periférico , Síncope Vasovagal/diagnóstico , Teste da Mesa Inclinada , Administração por Inalação , Adolescente , Adulto , Fármacos do Sistema Nervoso Central/administração & dosagem , Clomipramina/administração & dosagem , Feminino , Humanos , Injeções Intravenosas , Masculino , Pessoa de Meia-Idade , Nitroglicerina/administração & dosagem , Fármacos do Sistema Nervoso Periférico/administração & dosagem , Distribuição Aleatória , Recidiva , Adulto Jovem
6.
Am J Physiol Gastrointest Liver Physiol ; 294(1): G165-73, 2008 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-17975133

RESUMO

The reflex response to distension of the small intestine in vivo is complex and not well understood. The aim of this study was to characterize the neural mechanisms contributing to the complex time course of the intestinal secretory response to distension. Transmucosal potential difference (PD) was used as a marker for mucosal chloride secretion, which reflects the activity of the secretomotor neurons. Graded distensions (5, 10, and 20 mmHg) of distal rat duodenum with saline for 5 min induced a biphasic PD response with an initial peak (rapid response) followed by a plateau (sustained response). The rapid response was significantly reduced by the neural blockers tetrodotoxin and lidocaine (given serosally) and by intravenous (iv) administration of the ganglionic blocker hexamethonium and the NK(1) receptor antagonist SR-140333. Serosal TTX and iv SR-140333 significantly reduced the sustained response, which was also reduced by the NK(3) receptor antagonist talnetant and by the vasoactive intestinal polypeptide (VPAC) receptor antagonist [4Cl-d-Phe(6), Leu(17)]-VIP. Serosal lidocaine and iv hexamethonium had no significant effect on this component. Inhibition of nitric oxide synthase had no effect on any of the components of the PD response to distension. The PD response to distension thus seems to consist of two components, a rapidly activating and adapting component operating via nicotinic transmission and NK(1) receptors, and a slow component operating via VIP-ergic transmission and involving both NK(1) and NK(3) receptors.


Assuntos
Colo/efeitos dos fármacos , Duodeno/efeitos dos fármacos , Secreções Intestinais/efeitos dos fármacos , Mecanotransdução Celular/efeitos dos fármacos , Fármacos do Sistema Nervoso Periférico/farmacologia , Anestésicos Locais/farmacologia , Animais , Atropina/farmacologia , Cloretos/metabolismo , Colo/inervação , Colo/metabolismo , Duodeno/inervação , Duodeno/metabolismo , Inibidores Enzimáticos/farmacologia , Bloqueadores Ganglionares/farmacologia , Granisetron/farmacologia , Hexametônio/farmacologia , Antagonistas de Hormônios/farmacologia , Injeções Intravenosas , Lidocaína/farmacologia , Masculino , Potenciais da Membrana/efeitos dos fármacos , Camundongos , Camundongos Endogâmicos C57BL , Antagonistas Muscarínicos/farmacologia , Antagonistas dos Receptores de Neurocinina-1 , Óxido Nítrico Sintase/antagonistas & inibidores , Óxido Nítrico Sintase/metabolismo , Nitroarginina/farmacologia , Fármacos do Sistema Nervoso Periférico/administração & dosagem , Piperidinas/farmacologia , Pressão , Quinolinas/farmacologia , Quinuclidinas/farmacologia , Ratos , Ratos Sprague-Dawley , Receptores da Neurocinina-1/metabolismo , Receptores da Neurocinina-3/antagonistas & inibidores , Receptores da Neurocinina-3/metabolismo , Receptores 5-HT3 de Serotonina/metabolismo , Receptores de Peptídeo Intestinal Vasoativo/antagonistas & inibidores , Receptores de Peptídeo Intestinal Vasoativo/metabolismo , Antagonistas do Receptor 5-HT3 de Serotonina , Antagonistas da Serotonina/farmacologia , Tetrodotoxina/farmacologia , Fatores de Tempo , Peptídeo Intestinal Vasoativo/farmacologia
7.
J Knee Surg ; 18(1): 17-24, 2005 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-15742593

RESUMO

Perioperative injection of analgesic agents is widely used for postoperative pain control following knee arthroscopy. This prospective, randomized, double-blind study explored whether a preoperative analgesic injection offered better pain control than a postoperative injection. Patients undergoing knee arthroscopy under general anesthesia were randomized to receive a standardized combination of intra-articular bupivacaine, morphine, and epinephrine administered either 20 minutes prior to incision or at the end of the procedure. Outcome measures included visual analog pain scores at 0, 30, 60, 90, and 120 minutes after the procedure, total recovery room fentanyl consumption, total oral narcotics consumption for the first 24 hours after surgery, and a validated pain and satisfaction instrument. Of the 22 patients enrolled in the study, 21 successfully completed the study protocol. Pain scores, narcotics consumption, and overall patient satisfaction were not significantly different between the two groups. These findings indicate the timing of intra-articular analgesic injections during outpatient knee arthroscopy, either preoperatively or postoperatively, may be at the discretion of the surgeon.


Assuntos
Artroscopia/efeitos adversos , Bupivacaína/administração & dosagem , Epinefrina/administração & dosagem , Morfina/administração & dosagem , Dor Pós-Operatória/prevenção & controle , Fármacos do Sistema Nervoso Periférico/administração & dosagem , Método Duplo-Cego , Esquema de Medicação , Quimioterapia Combinada , Feminino , Humanos , Injeções Intra-Articulares , Articulação do Joelho/cirurgia , Masculino , Pessoa de Meia-Idade , Dor Pós-Operatória/etiologia , Satisfação do Paciente , Cuidados Pós-Operatórios , Cuidados Pré-Operatórios , Estudos Prospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA